Skip to main content
ALMR
NASDAQ Industrial Applications And Services

Alamar Biosciences Reports Q2 Revenue of $29.4M (+82% YoY), Guides FY2026 Revenue to $116M–$120M

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$28.99
Mkt Cap
$1.94B
52W Low
$18.845
52W High
$29.43
52W Position info
54% above low
Off High info
1.5% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

ALMR sits 54% above its 52-week low of $18.845.

Summary

Alamar Biosciences posted Q2 2026 revenue of $29.4 million, an 82% increase year-over-year, and guided for full-year revenue of $116–$120 million. Gross margins improved to 60%, and the company ended the quarter with $250 million in cash.


Key Events · Earnings and Guidance · ALMR

  • Q2 Revenue Surges 82%

    Total revenue reached $29.4 million in Q2 2026, up from $16.2 million in Q2 2025, driven by a 147% increase in consumables revenue to $15.5 million and a 35% increase in instrument revenue to $7.8 million.

  • Full-Year 2026 Guidance Initiated

    Management guided for full-year 2026 revenue of $116 million to $120 million, representing approximately 100% growth at the midpoint over 2025.

  • Gross Margin Expands to 60%

    Gross margin improved to 60% in Q2 2026 from 53% in Q2 2025, reflecting manufacturing efficiencies and a favorable shift toward higher-margin consumables.

  • Strong Balance Sheet with $250M in Cash

    Cash, cash equivalents and short-term investments totaled $250.1 million as of June 30, 2026, following $197.8 million in net IPO proceeds, providing ample runway for growth investments.


Analysis · ALMR · Industrial Applications And Services

Alamar Biosciences delivered strong Q2 results with revenue nearly doubling year-over-year, driven by rapid consumables pull-through and instrument placements. Gross margins expanded to 60% as manufacturing efficiencies kicked in. The company initiated full-year 2026 revenue guidance of $116M–$120M, implying ~100% growth at the midpoint. While net losses widened on heavy R&D and SG&A investment, the balance sheet is fortified with $250M in cash and equivalents post-IPO, and a new $60M revolving credit facility provides additional liquidity. The stock is trading near its 52-week high, reflecting market confidence in the growth trajectory.

At the time of this filing, ALMR was trading at $28.99 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $18.85 to $29.43. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ALMR - Latest Insights

ALMR
Aug 10, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $27.99
Real-time Price: $28.99 info
Change: +$1.00 (+4%) info
Market Cap: $1.94B info
ALMR
Aug 10, 2026, 4:03 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $27.99
Real-time Price: $28.99 info
Change: +$1.00 (+4%) info
Market Cap: $1.94B info
ALMR
Jul 13, 2026, 2:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $28.42
Real-time Price: $28.99 info
Change: +$0.570 (+2%) info
Market Cap: $1.94B info
ALMR
Jul 07, 2026, 4:55 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $25.23
Real-time Price: $28.99 info
Change: +$3.76 (+15%) info
Market Cap: $1.94B info
ALMR
May 08, 2026, 8:30 AM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $24.16
Real-time Price: $28.99 info
Change: +$4.83 (+20%) info
Market Cap: $1.94B info